The iQ Group Global collaborates with Harvard University’s Wyss Institute to explore the feasibility of a real-time, printable COVID-19 diagnostic test

The iQ Group Global has entered into a material transfer agreement with Harvard University’s Wyss Institute to explore whether a proprietary technology developed at the Wyss Institute could be used to help provide a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd […]

More

Explainer: Drug development, the regulatory process and the COVID-19 vaccine race

Athena Kolivos, Chief Scientific Officer CRC & Farmaforce The vaccine discovery and development experience unfolding for COVID-19 serves as a timely reminder that researching, developing and commercialising therapies to prevent, treat or cure life-threatening diseases is an extensive process; one that is very different from bringing everyday products and commodities to the marketplace. Across the […]

More

COVID-19 Q&A: Vaccine vs Antibody Test

In our series ‘COVID-19 Explained’, experts from The iQ Group Global demystify frequently asked questions about the COVID-19 virus.   This week, CRC and Farmaforce Chief Scientific Officer Athena Kolivos explains the difference between a vaccine and an antibody test, and why both are important in the fight against the COVID-19 pandemic.  What is a vaccine and […]

More

Cancer drug found to have ‘better staying power, reduced toxicity’ in preclinical trial – University of Texas at Austin

The below article was produced by The University of Texas at Austin and republished here with permission. UNIVERSITY OF TEXAS AT AUSTIN – A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects […]

More